Literature DB >> 10571771

The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

R E Gilbert1, M E Cooper.   

Abstract

Although the glomerulus, particularly the mesangium, has been the focus of intense investigation in diabetes, tubulointerstitial injury is also a major feature of diabetic nephropathy and an important predictor of renal dysfunction. The renal tubule in diabetes is subject to both direct and indirect pathogenetic influences as a consequence of its position in the nephron and its resorptive function. On exposure to glucose, proximal tubular cells elaborate vasoactive hormones, including angiotensin II and injurious cytokines such as transforming growth factor-beta (TGF-beta), as well as extracellular matrix proteins. In turn, angiotensin II may further increase TGF-beta expression in both proximal tubular and interstitial cells, thus amplifying the stimulus to fibrogenesis in the renal tubulointerstitium. In addition to these mostly direct influences, the renal tubule, particularly its proximal segment, is exposed to glomerular effluent. In the diabetic state, this includes large quantities of advanced glycation end products and glucose and, at later stages in the evolution of diabetic nephropathy, protein, all of which are factors that may induce TGF-beta expression and fibrosis. Diabetic nephropathy should therefore be viewed as a disease affecting the entire nephron. Continued exploration into tubulointerstitial disease in addition to glomerular injury in diabetes may help provide further insights into the pathogenesis of diabetic nephropathy and additional targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571771     DOI: 10.1046/j.1523-1755.1999.00721.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  197 in total

1.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 4.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

5.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

Review 6.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

7.  Clinical significance of fractional magnesium excretion (FEMg) as a predictor of interstitial nephropathy and its correlation with conventional parameters.

Authors:  Chie Noiri; Taisuke Shimizu; Kaori Takayanagi; Yosuke Tayama; Takatsugu Iwashita; Shimpei Okazaki; Minoru Hatano; Osamu Matsumura; Hitoshi Kato; Akihiko Matsuda; Tetsuya Mitarai; Hajime Hasegawa
Journal:  Clin Exp Nephrol       Date:  2015-02-28       Impact factor: 2.801

8.  Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.

Authors:  Daniel P K Ng; Charles L Hardy; Wendy C Burns; Evelyne E Muggli; Nicole Kerr; Jane McCausland; Daine Alcorn; Timothy E Adams; Jeffrey D Zajac; Richard G Larkins; Marjorie E Dunlop
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 9.  Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Authors:  Andrzej S Krolewski; Tomohito Gohda; Monika A Niewczas
Journal:  Clin Exp Nephrol       Date:  2013-11-12       Impact factor: 2.801

10.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Authors:  B J Davis; C I Johnston; L M Burrell; W C Burns; E Kubota; Z Cao; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2003-06-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.